Cagrilintide

Overview

Cagrilintide is a synthetic research peptide classified as an amylin analog. It is studied in laboratory environments for its potential to regulate appetite, support weight management, and enhance metabolic control in preclinical models such as laboratory rodents. Cagrilintide works by mimicking the effects of natural amylin, a peptide hormone co-secreted with insulin.

Benefits

In preclinical research, Cagrilintide has demonstrated the potential to reduce food intake, delay gastric emptying, and promote weight reduction in test subjects. Studies suggest it may complement other metabolic research compounds by providing additional appetite suppression and weight management effects in research models.
Source: Friedrichsen M, et al. Cagrilintide for weight management: a novel amylin analog in clinical trials. Diabetes, Obesity and Metabolism, 2021.

Possible Side Effects

In laboratory studies, test subjects administered Cagrilintide have displayed mild gastrointestinal effects, including reduced food intake, nausea-like responses, or slowed gastric emptying. Some test models have also shown mild injection site reactions or slight changes in gastrointestinal motility.
Source: Friedrichsen M, et al., Diabetes Obes Metab, 2021.

Dosage & Administration

Cagrilintide is administered via subcutaneous injection according to approved laboratory protocols. Typical research dosages range from 0.3 mg to 4.5 mg once per week, depending on the species, study design, and research objective. It may be combined with other peptides in studies exploring synergistic effects on weight management.
For laboratory research use only. Not for human consumption.

Summary

Cagrilintide is an amylin analog peptide developed exclusively for laboratory research exploring appetite regulation, gastric emptying, and weight management in preclinical models. Research indicates it may help reduce food intake and body weight with mild side effects such as injection site redness or slowed gastric emptying noted in test subjects. Cagrilintide is generally administered by subcutaneous injection once weekly, with dosage tailored to study goals and test species.
Strictly for research purposes only. Not for human use.